Table 1 Participant characteristics by study.
From: Exome-wide association study of levodopa-induced dyskinesia in Parkinson’s disease
Study | Discovery | Replication | |||
|---|---|---|---|---|---|
DISPGP | FRAGAMP | MNI-PD | |||
Disease status | LID | LID | Non-LID | LID | Non-LID |
No. of patients passing QC | 45 | 44 | 45 | 41 | 56 |
No. of males (%) | 20 (44%) | 34 (77%) | 36 (80%) | 23 (56%) | 37 (66%) |
Median follow-up time (years)a | 5.0 | 4.0 | 5.91 | 4.33 | 2.96 |
Mean age at PD onset (SD) | 57.8 (10.5) | 54.1 (8.2) | 55.0 (8.5) | 51.8 (10.8) | 58.9 (8.0) |
Mean age at start of l-dopa treatment (SD) | 60.3 (10.6) | 55.1 (8.2) | 56.9 (8.9) | 59.8 (9.1) | 61.8 (8.8) |
Mean age at LID onset (SD) | 65.4 (10.1) | 59.6 (8.3) | NA | 60.9 (9.9) | NA |
Mean age at examination (SD) | 68.1 (10.5) | 63.2 (7.6) | 62.3 (8.3) | 64.5 (9.1) | 66.2 (8.3) |
Hoehn–Yahr scale (SD) | 2.0 (0.7) | 2.5 (0.7) | 2.1 (0.8) | 2.4 (0.6) | 2.0 (0.6) |
